

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

INDUSTRIAL USES AND HANDLING OF P.P. (PHENYLACETONE, PHENYL-2-PROPANONE, AND BENZYL METHYL KETONE)

Solicitation of Information

The Drug Enforcement Administration has become aware that a compound known as P.P. and variously identified as phenylacetone, phenyl-2-propanone, and benzyl methyl ketone, has been reported used in the clandestine manufacture of amphetamine for trafficking purposes.

In view of this, DEA is studying P.P. in deciding whether control of it is necessary under the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 801-966) and regulations promulgated thereunder (21 CFR Part 1300 to end). These measures, if ultimately imposed, would regulate the manufacture, distribution and other handling of P.P. by requiring among other controls registration, security, and recordkeeping, and would make unauthorized use of P.P. unlawful.

DEA is aware this compound is used by industry in the preparation of polymers, selective solvents, flavoring agents, perfumes, insecticides, and antibacterial agents, and recognizes that DEA regulation of P.P. may have some effect upon these, and other industrial activities regarding the compound. However, DEA is not aware of the entire scope of use of P.P. by industry and therefore cannot predict the impact its regulation would have on them. To determine the extent of any such resulting impact, the Acting Administrator of the Drug Enforcement Administration invites all interested persons to provide DEA with any information on the manner of acquisition, consumption, storage, disposal and uses of P.P. by industry.

Such information may be submitted to the Special Programs Division, Office of Science and Technology, Drug Enforcement Administration, Washington, D.C. 20537, by November 1, 1975.

Dated: October 2, 1975.

HENRY S. DOGIN,
Acting Administrator,
Drug Enforcement Administration.

[FR Doc.75-27166 Filed 10-8-75;8:45 am]

CIBA-GEIGY CORP.

Manufacture of Controlled Substances;
Notice of Application

Section 303(a) (1) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 823(a) (1)) states:

The Attorney General shall register an applicant to manufacture controlled substances in schedule I or II if he determines that such registration is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on the effective date of this part. In determining the

public interest, the following factors shall be considered:

(1) maintenance of effective controls against diversion of particular controlled substances and any controlled substance in schedule I or II compounded therefrom into other than legitimate medical, scientific, research, or industrial channels, by limiting the importation and bulk manufacture of such controlled substances to a number of establishments which can produce an adequate and uninterrupted supply of these substances under adequately competitive conditions for legitimate medical, scientific, research, and industrial purposes;

Pursuant to § 1301.43 of Title 21 of the Code of Federal Regulations, notice is hereby given that on August 12, 1975, Pharmaceuticals Division, Ciba-Geigy Corporation, 556 Morris Avenue, Summit, New Jersey, made application to the Drug Enforcement Administration to be registered as a bulk manufacturer of methylphenidate, a basic class of controlled substance in schedule II.

Pursuant to section 301 of the Controlled Substances Act (21 U.S.C. 821), and in accordance with section 1301.43 (a) of Title 21 of the Code of Federal Regulations (CFR), notice is hereby given that the above person has made application to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic class of controlled substance indicated, and any other such person, and any existing registered bulk manufacturer of methylphenidate, may file written comments on or objections to the issuance of such registration and may, at the same time, file a written request for a hearing on the application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47. Such comments, objections and requests for a hearing may be filed no later than November 10, 1975.

Comments and objections may be addressed to the Hearing Clerk, Office of the Administrative Law Judge, Drug Enforcement Administration, Room 1130, 1405 Eye Street, N.W., Washington, D.C. 20537.

Dated: September 25, 1975.

HENRY S. DOGIN,
Acting Administrator,
Drug Enforcement Administration.

[FR Doc.75-27165 Filed 10-8-75;8:45 am]

Law Enforcement Assistant Administration
NATIONAL ADVISORY COMMITTEE ON
JUVENILE JUSTICE AND DELINQUENCY PREVENTION

Notice of Meeting

Notice is hereby given that the National Advisory Committee on Juvenile Justice and Delinquency Prevention and the three subcommittees will meet Wednesday, Thursday and Friday, October 29, 30, and 31, 1975, in Denver, Colorado. The meeting of the full Committee is scheduled to convene at 9:30 a.m., Thursday, October 30, in Conference Rooms B and C, Denver Airport

Hilton Inn, Denver, Colorado. The full Committee meeting is scheduled to adjourn at 5:00 p.m. on Thursday, resume at 9:00 the next day, and will adjourn at 5:00 p.m. on Friday. The Subcommittee on Standards will meet between 1:00 p.m. and 5:00 p.m. on Wednesday, October 29, 1975.

Discussions at the full Committee meeting will focus on:

The First Annual Report of the Office of Juvenile Justice and Delinquency Prevention, submitted to the President and Congress on September 30, 1975.

The development of the First Comprehensive Plan for juvenile justice and delinquency prevention, which is due March 1, 1976.

Subcommittee reports.

The Advisory Committee for the National Institute for Juvenile Justice and Delinquency Prevention (the National Institute Prevention Committee), the Advisory Committee on Concentration of Federal Effort (the Concentration of Federal Effort Committee) and the Advisory Committee to the Administrator on Standards for the Administration of Juvenile Justice (the Standards Committee) will meet from 1:30 p.m. to 4:00 p.m. on Thursday, October 30.

All meetings will be open to the public.

For further information, contact Mr. Frederick P. Nader, Acting Assistant Administrator, Office of Juvenile Justice and Delinquency Prevention, Law Enforcement Assistance Administration, 633 Indiana Avenue, N.W., Washington, D.C. 20531.

GERALD H. YAMADA,
Attorney Advisory,
Office of General Counsel.

[FR Doc.75-27144 Filed 10-8-75;8:45 am]

NATIONAL ADVISORY COMMITTEE ON
CRIMINAL JUSTICE STANDARDS AND GOALS

Notice of Meeting

This is to provide notice of meeting of the Research and Development Task Force on Criminal Justice Standards and Goals.

The Research and Development Task Force will meet on October 31, 1975 at the Mayflower Hotel, 1127 Connecticut Avenue, N.W., Washington, D.C. 20036. The meeting will convene at 9:30 a.m. and will be open to the public.

This is the first meeting of the Research and Development Task Force. Discussion will focus on the functions and duties to be performed by the Task Force members and staff.

For further information, contact William T. Archey, Director, Policy Analysis Division, Office of Planning and Management, 633 Indiana Avenue, N.W., Washington, D.C.

GERALD H. YAMADA,
Attorney-Advisor,
Office of General Counsel.

[FR Doc.75-27149 Filed 10-8-75;8:45 am]